MARATTO

article · PLoS ONE

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria

201736 citationsOpen accessUniversité de Kinshasa (UNIKIN)

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

The relative changes in plasma lactate concentration assessed at 8 or 12 hours after admission are valid surrogate endpoints for severe malaria studies on antimalarial drugs or adjuvant treatments aiming at improving the microcirculation. Measures of coma recovery are not valid surrogate endpoints for mortality.

Research topics

  • Malaria Research and Control
  • Hepatitis C virus research
  • Liver Disease and Transplantation

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1371/journal.pone.0169307

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.